Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Tivozanib
CHF 96.00
In stock
SYN-1013-M0011 mgCHF 96.00
SYN-1013-M0055 mgCHF 156.00
SYN-1013-M01010 mgCHF 221.00
SYN-1013-M05050 mgCHF 724.00
SYN-1013-M100100 mgCHF 1'185.00
| Product Details | |
|---|---|
| Synonyms | AV-951 |
| Product Type | Chemical |
| Properties | |
| Formula | C22H19ClN4O5 |
| MW | 454.9 |
| CAS | 475108-18-0 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: VEGFR | Kinase Group: RTK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | SPMVMDHWKHCIDT-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Tivozanib is a potent inhibitor of VEGFR-1, 2 & 3 (IC(50) 0.21, 0.16 and 0.24nM respectively).
Product References
- Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors: F.A. Eskens, et al.; Clin. Cancer Res. 17, 7156 (2011)
Related Products
